Our Approach
Our Investment Approach
Accelerating Growth Through Active Investment
We actively work with management teams and investment partners to help the underlying business achieve its full potential.
Sourcing Opportunities
We identify undervalued assets via our Executive Network, Medical Panel, and Family Office relationships, giving us proprietary access to off-market deals.
Pillar 01
Due Diligence
We assess portfolio-level financial data to mitigate blind-pool risk and secure positions at favourable pricing relative to NAV.
Operational Involvement
From board positions to interim C-suite appointments, PEAL Capital actively restructures and scales portfolio companies to deliver sustainable growth.
Strategic Governance
We collaborate with management teams to shape long-term strategies, align incentives, and monitor key performance metrics.
Pillar 04
Value Realisation
We plan and execute disciplined exits, delivering shorter holding periods and strong risk-adjusted returns for investors.
Pillar 05
Sector Expertise
Our focus on the longevity and hormone sectors allows us to bring unique insight and value to a fast-growing healthcare market.
Pillar 06
Frequently Asked Questions
FAQs
01. What sectors does the fund prioritise?
PEAL is deeply focused on opportunities within the Longevity & Hormones space. Our thesis targets the demographic forces reshaping health: longer healthspans, rising demand for hormone therapies, and a shift from treatment to prevention. We invest across four pillars: medical training, telemedicine, diagnostics, and specialty-drug distribution, to drive scale, data integration, and faster adoption of evidence-based care.
The fund seeks companies where it can create value through active, operational ownership, often in areas underserved by traditional institutional capital.
02. What is the geographic focus of the fund?
PEAL focuses its investment strategy across Western Europe, the US, Australia, and the Middle East. While the team primarily sources transactions within Europe, it also considers international expansion through add-on acquisitions. A clear example of this is the fund’s first portfolio company, Derma Medical, a medical training business which launched operations in the US within nine months of investment. PEAL is currently exploring the acquisition of a US-based medical training provider as a complementary addition to support Derma Medical’s growth in the US.
03. What level of control does PEAL seek in its investments?
PEAL targets traditional buyout investments where it can secure majority ownership or a controlling equity stake. This approach ensures the fund has significant governance rights, allowing it to actively guide and support the growth and development of its portfolio companies.
04. What is the typical investment size?
Operating in the lower mid-market segment, PEAL typically invests equity cheques ranging from $10 million to $50 million. This range allows the fund to target well-established businesses with meaningful scale, while still offering room for growth and transformation.
05. How does PEAL source investment opportunities?
The fund’s deal flow is exclusively off-market and opportunistic, stemming largely from its extensive network of operating partners, medical professionals, and advisors. PEAL builds relationships with business owners who value trust, discretion, and execution certainty over a competitive auction process. Many of these opportunities emerge in sectors such as longevity, menopause, and specialist healthcare, where the fund’s medical networks offer a distinct sourcing advantage.
06. How does PEAL select investment opportunities?
PEAL targets high-quality businesses poised to benefit from its hands-on support, whether they need operational restructuring or are mature organisations with strong products but unrealised growth potential. Drawing on a seasoned network of Operating Partners, the firm sharpens strategy, governance and execution across every portfolio company.
07. Does PEAL engage in any industry support activities?
PEAL is committed to supporting diversity and inclusion within the private equity industry. The firm is actively involved in several organisations that champion women in finance, including 100 Women in Finance, Level 20, and the Private Equity Women’s Network (PEWN).